What kind of company is Viberzi?

About Viberzi

Viberzi, also known as eluxadoline, is a medication used to treat irritable bowel syndrome with diarrhea (IBS-D). It was approved for use in the United States in 2015, and it is manufactured by Allergan, which was later acquired by AbbVie. This medication is designed to alleviate symptoms such as abdominal pain and diarrhea in patients with IBS-D.

How Viberzi works

Viberzi works by targeting receptors in the gut that help regulate bowel function. Specifically, it binds to specific receptors in the gut that help to reduce contractions which can cause diarrhea. By reducing excessive contractions, it helps to alleviate diarrhea and decrease abdominal pain.

Side effects

Like all medications, Viberzi can cause side effects. Some of the most common side effects include constipation, nausea, and abdominal pain. In rare cases, it can also cause pancreatitis, a serious inflammation of the pancreas. In 2017, the FDA issued a safety alert warning about the risk of pancreatitis associated with Viberzi use, especially in patients without a gallbladder.

Availability and cost

Viberzi is available only with a prescription in the United States. It is typically taken as a tablet twice a day with food. The cost of Viberzi varies depending on several factors, such as insurance coverage, the dosage, and the pharmacy you use. On average, a monthly supply of Viberzi costs around $1,300 in the United States, making it an expensive medication compared to other IBS-D treatments.

Overall, Viberzi is a medication used to treat IBS-D, and it works by targeting receptors in the gut to regulate bowel function. It can cause side effects, including pancreatitis, and it is available with a prescription in the United States. Due to its high cost, it may not be accessible for all patients with IBS-D.